Skip to main content

Table 1 Overall dropout rate and main reasons for treatment discontinuation in RCT

From: Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience

Author [ref]

N

duration (months)

Mean ± SD age, years

M/F Ratio

Drop-out rate (%)

Patient decision (%)

Lack of efficacy (%)

Adverse events (%)

Other Causes (%)

Busse et al. 2001 [16]

268

7

39.3

0.63

7.1

4.1

0.37

0.74

1.49

Soler et al. 2011 [23]

274

7

40.0

1.06

6.9

1.09

1.09

NR

NR

Holgate et al. 2004 [21]

126

8

41.1

0.55

8.7

8.7

NR

NR

NR

Ayres et al. 2004 [19]

206

12

37.5

0.39

7.3

NR

NR

7.3

NR

Vignola et al. 2004 [24]

209

7

38.3 ± 14.7

0.92

8.1

8.1

NR

NR

NR

Humbert et al 2005 [22]

209

7

43.4 ± 13.3

0.48

12.2

NR

NR

4.5

NR

Hanania et al. 2011 [20]

427

12

43.7 ± 14.3

0.63

19.4

11.00

NR

3.74

4.68

  1. F female, M male, NR not reported, RCT randomized controlled trials, SD standard deviation